Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF1 | P05230 | 2/20 | 0.44 |
| ▸ | FGF2 | P09038 | 2/20 | 0.44 |
| ▸ | VEGFA | P15692 | 2/20 | 0.44 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.41 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.41 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.41 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.38 |
| ▸ | CDC25B | P30305 | 5/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | SELP | P16109 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13057268 | 1.00 | FGF1 (0.44) | FGF1FGF2VEGFAHPSECA1 | |
| SCHEMBL6929305 | 1.00 | FGF1 (0.44) | FGF1FGF2VEGFAHPSECA1 | |
| SCHEMBL2175355 | 1.00 | FGF1 (0.44) | FGF1FGF2VEGFAHPSECA1 | |
| SCHEMBL13224917 | 0.92 | FGF1 (0.40) | FGF1FGF2VEGFAHPSECA1 | |
| SCHEMBL28316892 | 0.91 | FGF1 (0.52) | FGF1FGF2VEGFAHPSECA1 | |
| SCHEMBL13057307 | 0.91 | FGF1 (0.43) | FGF1FGF2VEGFAHPSECA1 | |
| SCHEMBL12406775 | 0.90 | BCHE (0.36) | FGF1FGF2VEGFAHPSECA1 | |
| SCHEMBL2532466 | 0.84 | SELP (0.36) | FGF1FGF2VEGFAHPSECA1 | |
| SCHEMBL2530520 | 0.84 | SELP (0.36) | FGF1FGF2VEGFAHPSECA1 | |
| SCHEMBL3398993 | 0.84 | SELP (0.36) | FGF1FGF2VEGFAHPSECA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6670361-B2 | Anticancer agents | TOYO SUISAN KAISHA, LTD. (JP) | 2003-12-30 | — | — | US | disclosed |
| US-6518410-B2 | Immunosuppressive agent, anticancer agent and DNA polymerase alpha inhibitor. | TOYO SUISAN KAISHA, LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| US-6518248-B1 | Method of treating gastric or colon cancer by administration of a sulfoquinovosylacylglycerol ester | TOYO SUISAN KAISHA, LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| US-20020173471-A1 | Method of treating cancer | TOYO SUISAN KAISHA, LTD. (JP) | 2002-11-21 | — | — | US | disclosed |
| US-6444795-B1 | ANTICANCER AGENTS | TOYO SUISAN KAISHA, LTD. (JP) | 2002-09-03 | — | — | US | disclosed |
| US-6395886-B1 | ANTICANCER AGENTS | TOYO SUISAN KAISHA, LTD. (JP) | 2002-05-28 | — | — | US | disclosed |
| US-20020052327-A1 | Novel sulfoquinovosylacylglycerol derivative, and use thereof as medicaments | TOYO SUISAN KAISHA, LTD. (JP) | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173471-A1 | Method of treating cancer | CPT1A, FASN, FADS1 | FGF1 408/4885FGF2 790/4885VEGFA 2750/4885 |
| US-20020052327-A1 | Novel sulfoquinovosylacylglycerol derivative, and use thereof as medicaments | SPTLC1, SULT2A1, SULT1A1 | FGF1 722/4885FGF2 729/4885VEGFA 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.